Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease
Managed Access Program (MAP) to Provide Access to Siponimod Treatment for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With no Satisfactory Alternative Treatment
Sponsor: Novartis Pharmaceuticals
A observational or N/A phase clinical study on Multiple Sclerosis, this trial is ongoing. The trial is conducted by Novartis Pharmaceuticals and has accumulated 9 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
No Longer Available
Status: Available → No Longer Available
-
Nov 2024 — Jan 2026 [monthly]
Available
-
Sep 2024 — Nov 2024 [monthly]
Available
-
Jul 2024 — Sep 2024 [monthly]
Available
-
Oct 2023 — Jul 2024 [monthly]
Available
▶ Show 4 earlier versions
-
Sep 2022 — Oct 2023 [monthly]
Available
-
Oct 2021 — Sep 2022 [monthly]
Available
-
Jan 2021 — Oct 2021 [monthly]
Available
-
Oct 2020 — Jan 2021 [monthly]
Available
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.